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Summary
Familial combined hyperlipidemia (FCHL) is a common
dyslipidemia predisposing to premature coronary heart
disease (CHD). The disease is characterized by increased
levels of serum total cholesterol (TC), triglycerides
(TGs), or both. We recently localized the first locus for
FCHL, on chromosome 1q21-q23. In the present study,
a genomewide screen for additional FCHL loci was per-
formed. In stage 1, we genotyped 368 polymorphic
markers in 35 carefully characterized Finnish FCHL
families. We identified six chromosomal regions with
markers showing LOD score (Z) values 11.0, by using
a dominant mode of inheritance for the FCHL trait. In
addition, two more regions emerged showing Z 1 2.0
with a TG trait. In stage 2, we genotyped 26 more mark-
ers and seven additional FCHL families for these inter-
esting regions. Two chromosomal regions revealed Z 1
in the linkage analysis: 10p11.2, (2.0 Z  3.20 v 
), with the TG trait; and 21q21, ( ),.00 Z  2.24 v  .10
with the apoB trait. Furthermore, two more chromo-
somal regions produced in the affected-sib-pairZ 1 2.0
analysis: 10q11.2-10qter produced with theZ  2.59
TC trait and with FCHL, and 2q31 producedZ  2.29
with the TG trait. Our results suggest addi-Z  2.25
tional putative loci influencing FCHL in Finnish families,
some potentially affecting TG levels and some poten-
tially affecting TC or apoB levels.
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Introduction
Familial combined hyperlipidemia (FCHL) is a common
dyslipidemia affecting ∼1%–2% of the populations in
Western societies (Grundy et al. 1987). FCHL is char-
acterized by elevated serum total cholesterol (TC), ele-
vated triglycerides (TGs), or both, with affected individ-
uals aggregating in families (Goldstein et al. 1973;
Nikkila¨ and Aro 1973). A consistent metabolic finding
in FCHL patients is increased apolipoprotein B (apoB)
concentration, although it is not clear whether an in-
creased production or decreased clearance of apoB-con-
taining lipoproteins predominates (Castro Cabezas et al.
1993; de Graaf and Stalenhoef 1998). Other metabolic
abnormalities in FCHL include glucose intolerance (Vak-
kilainen et al. 1998), insulin resistance (Aitman et al.
1997), and decreased adipocyte lipolysis (Reynisdottir
et al. 1995; Arner 1997). It is thus evident that FCHL
shares many features of the metabolic syndrome (Reaven
1988). As a consequence of these lipid disturbances,
FCHL patients are prone to early-onset coronary heart
disease (CHD). In fact, FCHL is one of the most common
familial dyslipidemias associated with premature CHD
(Genest et al. 1992).
The genetic component in combination with environ-
mental factors is predicted to play an important role in
the etiology of FCHL. However, difficulties resulting
from genetic heterogeneity, unknown mode of inheri-
tance, and lack of standardized diagnostic criteria for
FCHL have hampered studies aiming to reveal the mo-
lecular defect behind this disorder. By using the candi-
date-gene approach, researchers have investigated genes
encoding proteins that may be involved in FCHL path-
ophysiology. To date, the lipoprotein lipase gene (Gagne
et al. 1994; Reymer et al. 1995; Yang et al. 1995; Marcil
et al. 1996) and the apolipoprotein AICIIIAIV gene clus-
ter (Wojciechowski et al. 1991; Dallinga-Thie et al.
1454 Am. J. Hum. Genet. 64:1453–1463, 1999
1997; Wijsman et al. 1998) have been studied most thor-
oughly. However, contradictory data for the involvement
of these candidate genes have emerged. In addition to
inconsistent diagnostic criteria, population-based factors
may explain some of the contradictions with respect to
FCHL-candidate genes, because the alleles have different
frequencies in different populations, and environmental
risk factors may also differ substantially among popu-
lations (Kaufman et al. 1986). To summarize the can-
didate-gene studies, none of the genes examined seems
to explain the major genetic component of FCHL.
Genomewide scans are widely used for systematic
screening to identify possible susceptibility loci. In this
approach, no a priori knowledge of disease pathophy-
siology is presumed. To date, genomewide scans have
been done for a number of different complex diseases
(e.g., see Ginns et al. 1996; Hanis et al. 1996; Sawcer
et al. 1996) but not for FCHL. Our analysis of 10 chro-
mosomal regions containing candidate genes revealed
the first novel FCHL locus on chromosome 1q21-q23,
in the vicinity of the gene encoding apolipoprotein AII
(Pajukanta et al. 1998). However, the most obvious can-
didate genes in this region (apolipoprotein AII and the
selectin gene cluster) were positionally excluded, and,
most probably, this FCHL locus represents a novel, still-
unknown gene. To search for additional major loci mod-
ifying susceptibility to FCHL, we performed a genome-
wide scan in essentially this same set of Finnish families.
Subjects and Methods
Pedigrees
As part of the European Multicenter Study on Familial
Dyslipidemias (EUFAM) study (Porkka et al. 1997), 35
Finnish FCHL families were selected for genetic analyses
in stage 1, and 7 more were included in stage 2. Indi-
viduals from these 42 Finnish FCHL families were re-
cruited in the Helsinki (23 families), Turku (11 families),
and Kuopio (8 families) university hospitals as a part of
the EUFAM study (Pajukanta et al. 1998). The inclusion
criteria for probands were the following: age 30–55
years for men and 30–65 for women, premature CHD
confirmed by either angiography (38 probands) or my-
ocardial infarction (MI) (4 probands), and serum TC
and/or serum TGs equal to or greater than the age-
sex–specific 90th percentile. The CHD events were val-
idated on the basis of the medical records. At least two
physicians at the university hospitals confirmed the CHD
diagnosis of every proband, on the basis of either an-
giography (150% stenosis in one or more coronary ar-
teries) or MI. MI was diagnosed on the basis of the
following criteria: (1) typical clinical symptoms; (2) def-
inite electrocardiography findings, according to Min-
nesota coding (World Health Organization criteria)
(Rose et al. 1982); and (3) elevated levels of the creatine
kinase (CK) enzyme and its cardiac isoenzyme, CK-MB.
Individuals with type I diabetes, hypothyreosis, hepatic
or renal disease, or an LDL-receptor defect were ex-
cluded as probands. Details of the family collection have
been reported elsewhere (Porkka et al. 1997; Pajukanta
et al. 1998). We selected families in which, besides pre-
mature CHD, either the proband or a first-degree relative
had the combined phenotype IIB. As in our earlier study
(Pajukanta et al. 1998), family members were considered
to be affected with FCHL if they had either (a) both
elevated TC and elevated TGs (combined lipid pheno-
type) or (b) either high TC (phenotype IIA) or high TGs
(phenotype IV) (i.e., above the age-sex–specific 90th per-
centiles). In addition (in extended pedigrees), it was re-
quired that each individual with only elevated TC or
elevated TGs also had a first-degree relative with the
combined phenotype IIB, in order to be scored as af-
fected for the purpose of this analysis. This strategy has
been adopted to allow more certainty about the FCHL
diagnosis; elevation of only one lipid class (TC or TGs)
is common because of several environmental causes, as
well as because of genetic causes other than FCHL. This
strategy results in the ascertainment of a combined phe-
notype of FCHL.
The study design was approved by the ethical com-
mittees of the participating centers, and all samples were
collected in accordance with the Helsinki declaration.
All participants gave their informed consent.
Biochemical Analysis
All blood samples were taken after an overnight fast.
The lipid measurements were performed in the labora-
tories of the Helsinki and Kuopio university hospitals.
Serum TC and TGs were measured by enzymatic meth-
ods (Boehringer-Mannheim and Hoffman-La Roche).
Serum apoB was measured by immunoturbidimetric
methods (Orion Diagnostica and Kone Instruments).
Lipid-lowering medication was interrupted for 4 wk be-
fore blood sampling. The lipid criteria used for classi-
fication of study subjects ages 25 years were derived
from a large Finnish population study, FINMONICA
( ) (Vartiainen et al. 1994). The percentile val-n  6,022
ues for 60–65-year-olds were applied to all individuals
160 years old. The cutoff for the upper 90th percentile
of each phenotype distribution for subjects !25 years
old was derived from the follow-up samples in 1986 of
another large Finnish population study, the Cardiovas-
cular Risk Factors in Young Finns study ( )n  2,236
(Porkka et al. 1994). Lipid-assay differences between
centers were quantified in small subsamples (n  50–
) by linear regression analysis, and the levels were215
unified accordingly. The age-sex–specific 90th percen-
tiles for TC, TGs, and apoB for the Finnish population
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will be available on the National Public Health Institute
of Finland, Department of Human Molecular Genetics
Webpage. Familial hypercholesterolemia was excluded
from each pedigree by determination of the LDL-recep-
tor status of the proband, by the lymphocyte-culture
method (Cuthbert et al. 1986). Furthermore, in clinical
examination, none of the participants had tendon xan-
thomas. In the studied FCHL families, one to three lipid
measurements (the median being one measurement)
were obtained from each study subject for the lipid phen-
otyping. For classification purposes, the highest un-
treated lipid measurement was used.
Stage 1 and Stage 2: Genotyping of the Markers
DNA was extracted from EDTA blood according to
a standard procedure. In stage 1, a total of 368 micro-
satellite markers from a modified Weber screening set
(version 6) (Sheffield et al. 1995) were typed in 168
individuals from 35 Finnish FCHL families, of which
135 individuals were affected with FCHL. The “unaf-
fected” individuals were genotyped only to increase
phase information and were treated as if their pheno-
types were unknown in the statistical analysis, because
of the nondeterministic genotype-phenotype relationship
hypothesized for this complex phenotype (see the Sta-
tistical Analyses subsection, below). The average inter-
marker distance was 10.5 cM. Microtiter-well PCR am-
plification of the markers was automated by use of a
pipetting robot (Biomek 2000; Beckman). The fluores-
cently labeled PCR products were electrophoretically
separated on an automated laser fluorescence DNA se-
quencer ABI 377 (Perkin-Elmer), with GENESCAN (ver-
sion 2.1) fragment-analysis software. The alleles were
identified by the GENOTYPER program (version 2.0)
(Perkin-Elmer). The interpretation of alleles was checked
by two different individuals, to verify Mendelian seg-
regation. Some of the markers, which did not yield sat-
isfactory results after two PCRs and gel electrophoresis,
were replaced by additional linked markers from either
the Ge´ne´thon marker map (Dib et al. 1996) or the Co-
operative Human Linkage Center marker map (Sheffield
et al. 1995).
In stage 2, further analysis was conducted on the five
regions where the LOD score (Z) with the FCHL trait
was 11.0, under the assumption of a dominant mode of
inheritance. In addition, a denser marker map was stud-
ied in two further chromosomal regions where Z 1 2.0
with a second trait, elevated TGs. A denser marker map
for these initially interesting areas was analyzed by the
typing of 26 new markers. Seven additional FCHL fam-
ilies (33 individuals) were included in stage 2 of the
study. Altogether, 201 samples were genotyped for these
26 markers, by the ABI 377 sequencer. These additional
samples were typed both for all of these new markers
and for the markers producing the highest Z values in
stage 1. The markers analyzed in stage 2 were selected
and mapped on the basis of information derived from
the genetic maps of the Cooperative Human Linkage
Center and Ge´ne´thon.
Statistical Analyses
Two-point pairwise linkage analysis was performed
by the MLINK program of the linkage package (Lathrop
et al. 1984), FASTLINK version 2.2 (Cottingham et al.
1993; Scha¨ffer et al. 1994). The identity-by-descent
(IBD) status in the affected sib pairs (ASPs) was analyzed
by the SIBPAIR program (Kuokkanen et al. 1996). In
both stages, the data were analyzed with both linkage
analysis and ASP analysis. To control for the possibility
of bilineal transmission, etiologic heterogeneity, and po-
tential effects of inappropriate diagnostic classifications,
Z analysis was also done on the component nuclear ped-
igrees as if they were independent. Both ASP analysis
(which disregards parental-phenotype information) and
Z analysis of these nuclear pedigrees (which uses paren-
tal-phenotype information) were done. To circumvent
problems of incomplete penetrance and genetic ambi-
guity of the phenotype “unaffected,” an affecteds-only
strategy was used, by coding the subjects as either af-
fected or unknown, on the basis of the age-sex–specific
90th percentile for the measured lipids. The unaffected
family members were genotyped only to maximize the
marker-locus genotype and phase information. In ad-
dition to the FCHL trait, we also performed linkage
analyses treating elevated TC, TGs, or apoB separately,
using age-sex–specific 90th-percentile thresholds for the
affecteds, and again coded as unknown those individuals
with values lower than the 90th percentile. These anal-
yses were done to see whether we could identify any loci
predisposing to one of those traits individually that
might not be involved in the more extreme FCHL phe-
notype. As in our previous study (Pajukanta et al. 1998),
we performed linkage analyses by assuming disease-al-
lele frequencies of .006 under the dominant model and
.1095 under the recessive model, on the basis of the
proposed 1.0%–2.0% prevalence of FCHL (Grundy et
al. 1987). No phenocopies were allowed for. This ap-
proach used in linkage analysis is a Z equivalent of
model-free methods that reconstruct genotypes to make
every meiosis potentially informative for linkage at the
disease locus, as explained by Trembath et al. (1997)
and Terwilliger (1998). Thus, this method is equivalent
to model-free methods, even though linkage is used to
perform the likelihood computations. We also conducted
a multipoint analysis for the most positive markers iden-
tified in linkage analysis, using the same multipoint anal-
ysis strategy as we had adopted in our earlier study (Pa-
jukanta et al. 1998). The multipoint analysis was not
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Table 1
Results of the Two-Point Linkage Analysis and ASP Analysis with the Markers Resulting in Z 1 1.0
for the FCHL Trait
CHROMOSOME MARKER
MAXIMUM Za (v) IN LINKAGE ANALYSIS/Z IN ASP ANALYSIS
FCHL TG TC apoB
Stage 1:
1 D1S1677 1.36 (.08)/.82 .45 (.18)/1.02 .14 (.24)/.35 .00 (.50)/.00
8 D8S1128 1.54 (.14)/1.31 .58 (.16)/.21 .05 (.34)/.18 .06 (.32)/.03
9 D9S1122 1.11 (.12)/.70 .82 (.14)/.77 .12 (.26)/.05 1.18 (.12)/.74
10 D10S169 1.66 (.14)/2.23 .73 (.16)/.83 .92 (.16)/1.43 .94 (.16)/1.14
21 D21S1437 1.15 (.16)/.40 1.14 (.12)/1.29 .50 (.22)/.05 2.13 (.08)/.67
22 D22S683 1.00 (.22)/.98 .64 (.22)/.15 .47 (.24)/1.04 .31 (.28)/.79
Stage 2:b
8 D8S1128 1.37 (.16)/1.07 .77 (.16)/.13 .14 (.32)/.29 .09 (.30)/.01
9 D9S1122 .81 (.16)/.46 .71 (.16)/.67 .03 (.32)/.00 .72 (.18)/.41
10 D10S169 1.61 (.14)/2.29 .45 (.20)/.54 1.53 (.14)/2.59 1.00 (.16)/1.42
21 D21S1437 1.29 (.16)/.46 1.03 (.14)/1.38 .71 (.20)/.12 2.24 (.10)/.57
22 D22S683 .78 (.24)/.57 .53 (.24)/.03 .37 (.28)/.70 .15 (.32)/.34
a For a dominant mode of inheritance.
b For chromosome 1, no further markers were genotyped in stage 2, since the area overlapped the
novel FCHL locus region, 1q21-q23 (Pajukanta et al. 1998).
performed with flanking markers moving the disease
across the map, because of the known propensity for
false exclusions in that method (Risch and Giuffra
1992). To avoid the known negative side effects of mul-
tipoint analysis, we performed a multipoint analysis in
which the markers were placed in a fixed order and in
which the disease locus was allowed to vary outside the
map of markers (Terwilliger and Ott 1993), using the
MLINK program. Using this method, we found that mei-
oses uninformative for some markers can be scored for
nearby markers, thus allowing all meioses in all families
to be scored in the analyses.
For each marker, the allele frequencies were estimated
from the total study sample by an allele-counting
method. Genetic heterogeneity between the families was
tested by the HOMOG program (Ott 1991; Kuokkanen
et al. 1996).
Results
All the results obtained from the linkage analysis
adopting an affecteds-only strategy and from the ASP
analysis for all markers, with FCHL, TC, TGs, and apoB
as phenotypic traits, are available on the National Public
Health Institute of Finland, Department of Human Mo-
lecular Genetics Webpage.
FCHL Trait
In stage 1 of the genome scan, six markers, on chro-
mosomes 1, 8–10, 21, and 22, gave pairwise ,Z 1 1.0
by a dominant model for FCHL susceptibility in the
linkage analysis (table 1). The chromosome 1 marker
D1S1677, which produced ( ), over-Z  1.36 v  .08
lapped the area, on chromosome 1q21-q23, that, in an
earlier study (Pajukanta et al. 1998), we had identified
as a novel FCHL locus. In that study, this same marker
resulted in ( ). Of the families analyzedZ  0.91 v  .10
here, 31 of 35 in stage 1 had been included in our earlier
study. Consequently, no further markers were genotyped
in this area. The results of both the linkage analysis and
the ASP analysis of these six chromosomal regions are
given in table 1. The highest Z value was obtained on
chromosome 10q11.2-10qter, with the marker D10S169
( [ ]), in the ASP analysis (table 1).Z  2.23 P ! .0007
In stage 2, the interesting regions of chromosomes
8–10, 21, and 22 were studied further. Additional mark-
ers ( ) were genotyped in the 35 families and in 7n  20
additional families included in stage 2. The markers of
the initial scan that produced the highest Z values in
stage 1 were also genotyped in these seven families. Only
two of these regions were further supported in stage 2
(table 1). On chromosome 10, marker D10S169 resulted
in ( ) in the ASP analysis (table 1),Z  2.29 P ! .0006
and the nearby marker D10S1651 resulted in Z 
( ) in the ASP analysis. Furthermore, on0.84 P  .02
chromosome 21, marker D21S1437 resulted in Z 
( ) in the linkage analysis (table 1).1.29 v  .16
For chromosomes 8, 9, and 22, the Z values obtained
in linkage analyses decreased in stage 2. None of the
new markers in these regions resulted in , sug-Z 1 1.0
gesting that the initial , in stage 1, could haveZ 1 1.0
been due to chance. The detailed results for these chro-
mosomes in stage 2 are available on the National Public
Health Institute of Finland, Department of Human Mo-
lecular Genetics Webpage.
Markers D8S1128 and D10S169 (as described above)
also resulted in in the ASP analysis. In addition,Z 1 1.0
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Figure 1 Results of two-point linkage analysis with a dominant mode of inheritance, for individual markers genotyped for chromosome
10, in stage 1 and 2, with traits FCHL, TC, TG, and apoB.
there were four other markers resulting in in theZ 1 1.0
ASP analysis: D9S2169 ( in ASP analysis andZ  1.30
in linkage analysis [ ]), D11S4464Z  0.74 v  .10
( in ASP analysis and in linkage anal-Z  1.13 Z  0.71
ysis [ ]), D12S375 ( in ASP analysis andv  .22 Z  1.01
in linkage analysis [ ]), and D16S753Z  0.43 v  .18
( in ASP analysis and in linkage anal-Z  1.15 Z  0.85
ysis [ ]). A recessive mode of inheritance was alsov  .22
tested, both for these markers and for all other markers
on chromosomes 9, 11, 12, and 16, in two-point linkage
analysis of the 35 FCHL pedigrees. Except for D9S1122
(which was also detected with a dominant model for the
FCHL trait in the large pedigrees; see above), all the
markers in these four chromosomes resulted in Z !
when a recessive mode of inheritance in the extended1.0
pedigrees was assumed. This can be expected, given the
pedigree structure of the families that we studied, be-
cause, in our study material, a relatively small number
of sib pairs but multiple vertical transmissions were
available. Consequently, there are more relatives who
could share, at most, one allele—and not two al-
leles—identical by descent. Furthermore, the vertical re-
lationships, such as parent-child pairs, are not infor-
mative in the recessive analysis, because the recessive
analysis assumes that every affected individual has two
disease alleles, and therefore meioses to his/her children
are uninformative for linkage. No further markers were
genotyped in these regions.
Individual Specific Traits of High TC, High TG, and
High apoB
The results of the analyses of the individual lipid traits,
in stages 1 and 2, for the six regions potentially inter-
esting with regard to FCHL are presented in table 1,
together with the FCHL trait analyses. Figures 1 and 2
show theZ values for all markers typed on chromosomes
10 and 21, with each of the four traits, when a dominant
mode of inheritance is assumed in linkage analysis.
Other chromosomal regions where any of the individual
traits resulted in in two-point linkage analysisZ 1 1.0
and/or ASP analysis are presented in table 2.
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Figure 2 Results of two-point linkage analysis with a dominant mode of inheritance, for individual markers genotyped for chromosome
21, in stage 1 and 2, with traits FCHL, TC, TG, and apoB.
High TGs
In stage 1 of the genome scan, seven regions showed
in linkage analysis, and one region did so in ASPZ 1 1.0
analysis, with the TG trait (table 2). In two of these
chromosomal regions was obtained: on chro-Z 1 2.0
mosome 10, marker D10S1220 resulted in Z  2.57
( ) in linkage analysis, and, on chromosome 2,v  .00
marker D2S1391 resulted in ( ) in ASPZ  2.02 P  .001
analysis. The results of the statistical analysis for the TG
trait for the six regions identified with the FCHL trait
are shown in table 1.
In stage 2, the inclusion of the seven additional fam-
ilies increased the Z value for marker D10S1220, from
2.57 ( ) to 3.20 ( ), in linkage analysis, inv  .00 v  .00
the affecteds-only strategy (table 3 and fig. 1). Worth
noting is that these Z values were obtained at v  .00
and that no evidence of locus heterogeneity existed in
these analyses. The nearby marker D10S1233 resulted
in ( ). With the FCHL trait, markerZ  0.84 v  .10
D10S1220 resulted in ( ) in linkageZ  1.26 v  .04
analysis.
In stage 2, the Z value of marker D2S1391 increased
from 2.02 ( ) to 2.25 ( ), in ASP anal-P  .001 P  .0006
ysis (table 4). The most significant nearby marker (3.6
cM) was D2S148, with ( ) in ASPZ  0.78 P  .029
analysis (table 4).
High TC
In stage 1 of the genome scan, the highest Z value for
the TC trait was obtained by ASP analysis in one of the
six potentially interesting regions also identified for the
FCHL trait: marker D10S169 exhibited Z  1.43
( ) in ASP analysis (table 1). In addition, in stageP  .005
1, the TC trait alone produced three different regions
that, in both ASP analysis and linkage analysis, resulted
in (table 2), although in neither of the analysesZ 1 1.0
did any of the markers result in . In stage 2, theZ 1 2.0
Z value for marker D10S169 increased from 1.43
( ) to 2.59 ( ) with the TC trait, in ASPP  .005 P ! .0003
analysis (tables 1 and 4 and fig. 1).
High apoB
In stage 1 of the genome scan, the highest Z value for
the apoB trait, 2.13 ( ), was obtained, withv  .08
marker D21S1437 on chromosome 21, in linkage anal-
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Table 2
Genome-Scan Markers Resulting in inZ 1 1.0
Linkage Analysis or ASP Analysis, for Separate Traits
LOCUS
Z
Maximuma
Nuclear
Familyb ASP
TG trait:
D2S1326 1.395866 1.129947 .501995
D2S1391 1.22319 1.942121 2.023203
D5S408 1.086605 1.264405 1.033293
D7S1830 1.691056 1.659309 .843462
D10S1220 2.568114 1.386225 .496242
D13S800 1.910678 .883094 .706713
D14S742 1.064543 .885049 .405487
D6S1281 .263617 .415794 1.003509
TC trait:
D6S1006 1.320385 .777908 .974036
D11S4464 1.06793 1.220498 1.26089
D12S1659 1.046737 .339792 .406268
D15S816 .013376 .558894 1.057962
D15S657 .996662 .980203 1.43362
DXS6804 .569403 1.558509 1.179271
apoB trait:
D11S4464 1.07097 1.824949 1.610766
D15S153 1.05716 .306091 .397427
D16S753 1.170597 1.35869 1.321064
DXS6804 1.16265 1.690665 1.878295
D3S2398 .692005 .989974 1.009491
D6S1006 .498744 .552987 1.009014
D7S2201 .797234 .813216 1.101056
D15S816 .553682 .769874 1.128925
D16S2624 .230827 .969041 1.239194
a For a dominant mode of inheritance.
b For pedigrees divided into nuclear families.
Table 3
Z Values, in Linkage Analysis and ASP Analysis, for
Chromosome 10 with the TG Trait and Chromosome 21 with
the apoB Trait
LOCUS
DISTANCEa
(cM)
Z (v)b
Maximum
Nuclear
Family ASP
TG trait:
D10S1426 8 .19 (.22) .00 (.50) .00
D10S675c 2 .00 (.50) .00 (.50) .00
D10S1247c 3 .09 (.30) .07 (.30) .17
1.76 (.08)d
D10S1220e 4 3.20 (.00) 1.10 (.00) .23
3.13 (.01)d
D10S1233c 10 .84 (.10) .42 (.14) .47
D10S1225 .00 (.50) .00 (.50) .00
apoB trait:
D21S1432 3.5 .21 (.28) .33 (.24) .20
D21S1899c 4 .20 (.32) .35 (.26) .33
D21S1905c 1.5 .38 (.20) .13 (.26) .04
2.39 (.12)d
D21S1437e 3.5 2.24 (.10) 1.19 (.14) .57
.70 (.21)d
D21S1922c 4 .00 (.50) .03 (.36) .02
D21S272c 2.5 .00 (.50) .00 (.50) .00
D21S1435 .16 (.26) .11 (.28) .12
a Between the marker and that in the row immediately below.
b Definitions are as in the footnotes to table 2.
c Genotyped for the dense marker map in stage 2.
d Multipoint Z, by MLINK, between the two adjacent
markers.
e Genotyped in both stage 1 and stage 2.
ysis using the affecteds-only strategy, in one of the six
regions that are interesting with regard to FCHL (table
1). In addition, in stage 1, the apoB trait alone resulted
in four chromosomal regions showing in linkageZ 1 1.0
analyses, and three of these four also showed inZ 1 1.0
ASP analysis. Furthermore, five regions showed Z 1
in ASP analysis only (table 2). None of the markers1.0
in these nine regions revealed markers resulting in Z 1
, in either of the analyses.2.0
In stage 2, the Z value for the apoB trait, with the
chromosome 21 marker D21S1437, increased from 2.13
( ) to 2.24 ( ) in linkage analysis when thev  .08 v  .10
seven additional families were included (table 1 and fig.
2). The closest marker (at a distance of 1.5 cM),
D21S1905, resulted in , in linkage analysis (ta-Z  0.38
ble 3).
Contribution of Individual FCHL Families to Linkage
Findings
The results of the linkage analysis of the four potential
susceptibility loci identified for independent traits in this
study (loci for TGs, on chromosome 10p11.2 and on
chromosome 2q31; a locus for apoB, on chromosome
21q21; and a locus for TC, on chromosome 10q11.2-
10qter), as well as our earlier data on the FCHL locus
on chromosome 1q21-q23 (Pajukanta et al. 1998), dem-
onstrate that none of the individual families alone pro-
duced significant Z values (in the present study, the high-
est Z value obtained for an individual family was 0.64),
but the total Z value for these Finnish families represents
the sum of all families with no evidence for locus het-
erogeneity. Furthermore, there was no clear overlap be-
tween the families producing positive Z values in the
chromosome 1 region and those doing so in other
regions. The linkage data on all individual families, for
the markers with the highest Z values in these regions,
as well as phenotype information and lipid values for
the five most informative pedigrees, are available on the
National Public Health Institute of Finland, Department
of Human Molecular Genetics Webpage.
Multipoint Analysis
Our study material consisting of extended FCHL fam-
ilies is likely to be most informative in an analysis such
as the affecteds-only linkage analysis, which uses the
data on vertical transmission of the trait that are avail-
able in these families. Therefore, to analyze whether we
could extract more information from multiple markers,
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Table 4
Z Values, in Linkage Analysis and ASP Analysis, for
Chromosome 2 with the TG Trait and Chromosome 10 with
the TC Trait
LOCUS DISTANCEa
Zb
Maximum
Nuclear
Family ASP
TG trait:
D2S1776 12.4 .44 (.22) .69 (.14) .52
D2S148c 3.6 1.08 (.16) 1.47 (.10) .78
D2S1391d 3.3 1.95 (.08) 2.33 (.04) 2.25
D2S118c 4.5 .53 (.24) .70 (.16) .45
D2S117c 5.6 .46 (.22) .25 (.24) .21
D2S1384 .54 (.16) .38 (.20) .67
TC trait:
D10S1223 5 .40 (.22) .04 (.34) .03
D10S1727c 2.5 .23 (.26) .16 (.28) .30
D10S1655c 2.5 .00 (.50) .00 (.50) .00
D10S1134c 1 .00 (.50) .00 (.50) .00
D10S169d 2 1.53 (.14) 2.74 (.04) 2.59
D10S1675c 1.6 .00 (.50) .00 (.50) .00
D10S1770c 1.5 .02 (.38) .06 (.34) .03
D10S1651c .16 (.30) .38 (.24) .30
a Between the marker and that in the row immediately below.
b Definitions are as in the footnotes to table 2.
c Genotyped for the dense marker map in stage 2.
d Genotyped in both stage 1 and stage 2.
we conducted multipoint analysis with markers on
10p11.2 and 21q21, which, in the linkage analysis,
showed potential evidence of linkage with the TG and
apoB traits. To avoid the negative side effects of the
multipoint analysis (Risch and Giuffra 1992), we con-
ducted an analysis similar to that used in our earlier
study, which had revealed the first novel FCHL locus on
1q21-q23 (Pajukanta et al. 1998; also see the Statistical
Analyses subsection, above). Multipoint analysis did not
significantly add information content on the families that
we studied: for 10p11.2, the highest two-point Z value
with the TG trait was 3.20 ( ), whereas the highestv  .00
multipoint Z value for this region was 3.13 ( );v  .01
for 21q21, with the apoB trait, these values were 2.24
( ) and 2.39 ( ), respectively (table 3).v  .10 v  .12
Discussion
In the present study, we have performed a genomewide
screen for loci involved in susceptibility to the FCHL
phenotype, using 368 randomly spaced polymorphic
markers in stage 1 and using 26 additional markers, in
five interesting chromosomal regions, in stage 2. We
identified four chromosomal regions suggesting a pos-
sible involvement in the etiology of FCHL, in addition
to the earlier-characterized FCHL locus on chromosome
1q21-q23 (Pajukanta et al. 1998). The evidence for two
loci emerged from linkage analysis using a dominant-
inheritance model: a locus for susceptibility to elevated
TGs, on chromosome 10p11.2 ( [ ]), andZ  3.2 v  .00
a locus for susceptibility to elevated apoB levels, on chro-
mosome 21q21 ( [ ]). Two other poten-Z  2.24 v  .10
tial regions were detected with the ASP analysis: a telo-
meric region of chromosome 10, with (Z  2.59 P !
) with the TC trait (2.29 [ ] with the.0003 P ! .0006
FCHL trait) and a region on chromosome 2q31, with
( ) with the TG trait. Because weZ  2.25 P  .0006
performed the genome screen in essentially the same set
of families in which we had characterized the first FCHL
locus on 1q21-q23 (Pajukanta et al. 1998), our results
would suggest that, in these FCHL families from the
Finnish population, there is one major FCHL locus on
1q21-q23. The evidence presented here further suggests
that multiple additional loci might affect the expression
of different component traits that form the complex
FCHL phenotype. However, it is evident that all four of
these suggestive regions need to be further analyzed in
other study samples, to clarify whether they truly harbor
loci predisposing to FCHL, because multiple tests were
performed, and the highest Z value in pairwise linkage
analysis was 3.2 for the locus on chromosome 10p11.2.
The four potential susceptibility loci of individual
traits identified show that different loci are identified
with component traits forming the complex FCHL
phenotype. There was no clear overlap between the in-
dividual families producing positiveZ values in the chro-
mosome 1 region identified in our earlier study (Paju-
kanta et al. 1998) and those that did so in the regions
characterized in the present study. Furthermore, none of
the individual families alone produced significant Z val-
ues, but the total Z value represents the sum of all fam-
ilies with no evidence for locus heterogeneity. We find
that this is a reasonable result, because there are likely
to be different genes involved in the different specific
phenotypes, unrelated to the pathological combination
of them. Furthermore, the fact that the traits are not
100% correlated indicates that some differences in the
genetic basis of each trait probably exist. Our data also
support the commonly suggested concept that FCHL is
a heterogeneous disease with several loci affecting the
complex phenotype (Cullen et al. 1994; Jarvik et al.
1994; Juo et al. 1998).
Linkage analysis of extended families has been, so far,
the most successful locus-mapping method, for complex
disease and simple disease alike (St. George-Hyslop et
al. 1987; Hall et al. 1990; Pericak-Vance et al. 1991).
FCHL was originally proposed to be inherited as an
autosomal dominant disorder (Goldstein et al. 1973),
which would be in accordance with the inheritance pat-
tern in our FCHL families, because a dominant inheri-
tance of a risk factor is the most consistent explanation
for a genetic risk factor leading to correlations between
phenotypes of relatives in different generations, such as
was observed in these families. If the risk factor were
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recessive, then, for risk, there would always be higher
correlations within generations than between genera-
tions. However, in complex diseases such as FCHL, in
which the interplay of multiple genes and environmental
factors are necessary for the complicated phenotype to
be expressed, it is evident that assumptions about the
mode of inheritance represent oversimplifications. The
disease aggregates in families yet does not segregate in
a simple manner, making the determination of the ge-
notype-phenotype relationships much more difficult
than it is for simple monogenic traits. Therefore, a more
complex polygenic background is also likely in FCHL,
as has been suggested by metabolic (de Graaf and Stal-
enhoef 1998) and segregation studies (Cullen et al. 1994;
Jarvik et al. 1994). Thus, to avoid oversimplifications
concerning the genetic component, we performed both
linkage analysis adopting an affecteds-only strategy and
ASP analysis, in 35 extended Finnish FCHL families, in
stage 1, and then in these 35 families and 7 additional
families , in stage 2. The affecteds-only strategy was
selected to minimize problems of incomplete penetrance,
whereas the ASP analysis circumvents some of the errors
incumbent in Z analysis, such as an incorrectly para-
meterized mode of inheritance for the complex disease.
Two loci obtained with each analysis method were fur-
ther supported by stage 2 of the genome scan, thus sug-
gesting a potentially dominant-inheritance pattern for
the loci on 10p11.2 and 21q21 and a recessive-inheri-
tance pattern for loci on 10q11.2-10qter and 2q31. No
significant evidence was found for locus heterogeneity,
in any of the trait/marker combinations tested.
In all FCHL studies, the diagnosis of FCHL includes
dyslipidemia in the proband, and in most re-
ports—including the original ones by Goldstein et al.
(1973) and Nikkila¨ and Aro (1973)—CHD in the family
is required. Accordingly, in most studies so far, the fam-
ilies have been ascertained through clinical sources.
Therefore, in the absence of further studies, the results
of these investigations cannot be generalized to the pop-
ulation level.
The isolated Finnish population has well-established
advantages for the mapping of monogenic diseases
(Ha¨stbacka et al. 1992; de la Chapelle 1993; Peltonen
et al. 1995) that are caused by a characteristic single
ancestral mutation. Such a strong founder effect is not
expected for complex diseases, in which the suscepti-
bility alleles are likely to be far more common. In the
best case, the mutant allele and its corresponding set of
haplotypes predate the founding of the Finnish popu-
lation, with still potentially multiple haplotypes existing
even in the founder population. In the worst case, mul-
tiple different mutations on different haplotype back-
grounds may exist in the same gene even in this isolat-
ed population. However, in any case, because of the
relatively small effective population size of the Finnish
population, there is likely to be less allelic and locus
heterogeneity here than in more mixed populations,
making it potentially easier to map complex traits as
well—although perhaps not as much so as is the case
for rare monogenic recessive diseases.
Environmental factors have also been shown to differ
substantially between populations (Kaufman et al.
1986). On the basis of the geographic, linguistic, and
cultural factors that caused the Finnish genetic isolation
and homogeneity of the population (de la Chapelle
1993; Peltonen et al. 1995), it is reasonable to expect
smaller variations in both the environmental factors and
life-style in Finland than is seen in a random sample
from a more mixed population. This may be especially
important in familial lipid disorders such as FCHL, in
which an interplay between several environmental fac-
tors effecting lipid levels and multiple genes may act
synergistically to lead to such complex disease pheno-
types. In fact, genomewide scans using material collected
from internal isolates of Finland have already been suc-
cessful in the study of such other complex diseases as
multiple sclerosis (Kuokkanen et al. 1996) and in type
2 diabetes (Mahtani et al. 1996). In the family material
that we studied, which provides well-defined phenotype
and diagnostic criteria (Pajukanta et al. 1998), we found
some evidence for four potential susceptibility loci for
FCHL, two of them having an impact mainly on TGs,
one on apoB, and one on TC. These data would be
consistent with earlier complex-segregation analyses, in
which there is evidence for both a major locus affecting
serum TGs in FCHL (Cullen et al. 1994) and a major
locus affecting apoB levels (Jarvik et al. 1994).
The chromosome 10 finding in the present study is
interesting because two potential candidate genes are
initially positioned in this region, on 10p11.2. One of
them is the fibronectin-receptor beta-subunit precursor
gene (beta-1 integrin VLA4) (Argraves et al. 1987),
which belongs to the adhesion receptors and interacts
with the vascular cell–adhesion molecule 1 (VCAM1)
on leukocytes. de Gruijter et al. (1991) have shown that
FCHL patients exhibit a significantly increased cell ad-
hesion to endothelial cells. Another candidate gene in
this region is the glutamic acid decarboxylase 1 (GAD1)
gene encoding a target for autoantibodies in people who
later develop insulin-dependent diabetes (Baekkeskov et
al. 1990). However, because biological evidence sup-
porting the role of these genes in FCHL is currently
lacking, further studies constructing a physical map over
the linked region and looking for either intragenic poly-
morphisms of these candidate genes or any novel tran-
script in this region are warranted.
In conclusion, our data on four putative loci influ-
encing serum lipid levels would suggest that these loci
newly identified in the present study could modify the
TG, TC, and apoB traits and, in combination with the
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FCHL locus on 1q21-q23, result in the complex FCHL
phenotype. However, further studies are warranted in
this family material and in independent family sets, to
clarify the true significance of these loci or any other
FCHL locus.
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